Discover and read the best of Twitter Threads about #gi23

Most recents (3)

@TumorBoardTues @MPishvaian @JohnEbbenMDPhD @CCAlliance 1/22 #TumorBoardTuesday #ColonCancerAwarenessMonth #OncTwitter @shafiarahman_

62 yo 👨🏼‍🦳 asymptomatic
🔦 Screening colonoscopy - sigmoid mass
🔬Biopsy + for pMMR/MSS adenocarcinoma
🩻Staging CT + for unresectable liver mets

🤨What first line systemic treatment would you choose?
@TumorBoardTues @MPishvaian @JohnEbbenMDPhD @CCAlliance @shafiarahman_ 2/22 #TumorBoardTuesday @MPishvaian @JohnEbbenMDPhD #CRCAwarenessMonth

👨🏼‍🦳started on first line FOLFOX
🧪NGS testing
KRAS/BRAF WT
TMB low
ERBB2 negative
ATM mutation
@TumorBoardTues @MPishvaian @JohnEbbenMDPhD @CCAlliance @shafiarahman_ 3/22 #TumorBoardTuesday #GI23 #CRCAwareness
👩🏻‍🏫Mini tweetorial 1👨🏻‍🏫

↩️Left side tumors more common:
BRAF WT
KRAS WT
HER2 amp

↪️Right side tumors enriched for
BRAF V600E mutation
KRAS Mut
MSI-H
📚@ASCO
Read 29 tweets
@MPishvaian #GI23
Coming at you from #TumorBoardTuesday
The TOP 🎯💊abstracts for ASCO-GI 2023

➡️Starting with MSI-H cancers:
✅Path CR neoadj ICI MSI-H GI Cancers
👁️L Pappas, Abs 43, Pos B18

✅A Ph 2 trial of toripalimab in adv tumors with POLE/POLD1🧬mut
👁️Y Jin, Abs 802, Pos M17
@MPishvaian #GI23
➡️Exciting updates in HER2➕Cancers

✅A Ph 2 trial of trast➕pertuz vs. iri➕cetuximab for HER2➕mCRC: SWOG S1613
👁️KPS Raghav, Abs 140, Pos G18

✅Zanidatamab➕chemo as 1⃣st-line Tx for HER2➕met GE jxn AdenoCa
👁️Ea Elimova, Abs 347, Pos E8
@MPishvaian #GI23
➡️Several CRC-specific🎯💊trials:

✅A Ph Ib trial of dabraf➕tramet➕iri➕cetux in BRAF V600E-mut mCRC
👁️Y Chen, Abs 156, Pos H15

✅A TAPUR trial update of Olaparib for pts with ATM-mut mCRC
👁️D Behl, Abs 122, Pos F19
Read 6 tweets
😀I am so excited to be at my 1⃣st IN PERSON ASCO GI in 3y

✅To prepare, I have gone through the abstract titles, and here are my Top GI ASCO 2023 abstracts

📣Disclaimer: There is no bias or exclusion intended.
These are just the ones I personally want to see👀
#GI23
➡️Starting with #Cholangiocarcinoma because it is a big year - especially because of:
✅SWOG 1815: A phase III trial of gem-cis-nab-pac vs. gem-cis as 1⃣st line💊for advanced BTC
👁️Rachna Shroff, Abs LBA490
@rachnatshroff
#GI23
➡️Two impt ImmunoTx trials:
✅IMbrave151: Phase 2 trial of gem-cis-atezo + /- bev as 1⃣st line💊for advanced BTC
👁️A El-Khoueiry, Abs 491

✅Also a TOPAZ-1 report on the long-term survivors Txed with gem-cis-durva 1⃣st line for advanced BTC
👁️M Bouattour, Abs 531, Pos C1
Read 21 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!